Sepracor working with SmithKline on R-ketoprofen OTC analgesic project.
This article was originally published in The Tan Sheet
Executive Summary
SEPRACOR WORKING WITH SMITHKLINE ON R-KETOPROFEN OTC ANALGESIC PROJECT, Sepracor Chief Financial Officer David Southwell told securities analysts at the Dillon, Read generic drug and drug delivery conference in New York City May 11. SmithKline Beecham has recently taken over the project following its acquisition of the Sterling Winthrop OTC business outside the U.S. Sepracor and Sterling signed a co-development agreement on the single-isomer version of ketoprofen in December 1992, under which Sterling received worldwide OTC marketing rights.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning